Bristol-Myers Squibb (NYSE:BMY) Shares Bought by Twin Capital Management Inc.

Twin Capital Management Inc. boosted its holdings in shares of Bristol-Myers Squibb (NYSE:BMY) by 13.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 83,162 shares of the biopharmaceutical company’s stock after acquiring an additional 9,831 shares during the quarter. Twin Capital Management Inc.’s holdings in Bristol-Myers Squibb were worth $4,267,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. OFI Invest Asset Management acquired a new stake in Bristol-Myers Squibb during the third quarter worth $25,000. True Wealth Design LLC purchased a new position in shares of Bristol-Myers Squibb during the fourth quarter worth $26,000. Milestone Investment Advisors LLC purchased a new position in shares of Bristol-Myers Squibb during the third quarter worth $27,000. Coppell Advisory Solutions LLC purchased a new position in shares of Bristol-Myers Squibb during the second quarter worth $28,000. Finally, Blue Bell Private Wealth Management LLC boosted its position in shares of Bristol-Myers Squibb by 61.5% during the third quarter. Blue Bell Private Wealth Management LLC now owns 525 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 200 shares during the period. Institutional investors and hedge funds own 76.41% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on BMY shares. William Blair restated a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Monday, April 1st. Wells Fargo & Company lifted their target price on Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a report on Thursday. Bank of America lowered Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and decreased their target price for the company from $68.00 to $60.00 in a report on Wednesday, January 3rd. Redburn Atlantic lowered Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and decreased their target price for the company from $77.00 to $54.00 in a report on Tuesday, February 6th. Finally, Societe Generale lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Monday, March 11th. One equities research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $61.18.

Bristol-Myers Squibb Stock Performance

BMY traded up $0.05 during trading on Thursday, reaching $47.89. The company’s stock had a trading volume of 4,518,421 shares, compared to its average volume of 15,692,369. Bristol-Myers Squibb has a 52-week low of $47.58 and a 52-week high of $70.93. The company’s fifty day moving average price is $51.26 and its 200-day moving average price is $51.59. The company has a market capitalization of $97.06 billion, a price-to-earnings ratio of 12.46, a price-to-earnings-growth ratio of 1.49 and a beta of 0.39. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.31 and a current ratio of 1.43.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $1.70 EPS for the quarter, topping the consensus estimate of $1.55 by $0.15. The business had revenue of $11.48 billion for the quarter, compared to analyst estimates of $11.19 billion. Bristol-Myers Squibb had a return on equity of 50.95% and a net margin of 17.83%. The company’s quarterly revenue was up .6% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.82 EPS. On average, equities analysts forecast that Bristol-Myers Squibb will post 6.47 earnings per share for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, May 1st. Stockholders of record on Friday, April 5th will be paid a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a dividend yield of 5.01%. The ex-dividend date is Thursday, April 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 62.18%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.